Neuberger Berman Group
OTLK icon

Neuberger Berman Group’s Outlook Therapeutics OTLK Stock Holding History

Neuberger Berman Group’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,337
Closed -$26.3K – 1897
2023
Q4 		$26.3K Buy
3,337
+1,924
+136% +$16.3K ﹤0.01% 1842
2023
Q3 		$6.25K Buy
+1,413
New +$31.3K ﹤0.01% 1798

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Neuberger Berman Group's OTLK Position: Q1 2024 in Review

Neuberger Berman Group sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 3,337 shares — an estimated $26.3K sold.

Neuberger Berman Group first reported a position in OTLK in Q3 2023 and held it in 2 quarters. The position peaked at $26.3K in Q4 2023. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • Neuberger Berman Group reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Neuberger Berman Group sold 3,337 Outlook Therapeutics shares in Q1 2024, an estimated $26.3K.
  • Neuberger Berman Group first reported a position in Outlook Therapeutics in Q3 2023 and held it in 2 quarters.
  • Neuberger Berman Group's Outlook Therapeutics position peaked at $26.3K in Q4 2023.
  • 56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on Neuberger Berman Group's 13F filing for Q1 2024, filed 13 May 2024.